文献速递艾滋病与性传播感染

病毒学抑制且骨量减少的HIV感染成人从替诺福韦二吡呋酯联合拉米夫定或恩曲他滨联合利托那韦增效蛋白酶抑制剂简化为利托那韦增效阿扎那韦联合拉米夫定的先导研究

Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

单臂先导研究纳入31例病毒学抑制但骨密度低的HIV感染成人,将含替诺福韦二吡呋酯加利托那韦增效蛋白酶抑制剂的三联方案转换为利托那韦增效阿扎那韦100/300 mg联合拉米夫定300 mg每日一次。48周时脊柱和髋部骨密度均较基线升高,骨转换标志物和尿替诺福韦毒性标志物改善,无病毒学失败或严重不良事件。

要点

  • 转换为利托那韦增效阿扎那韦联合拉米夫定后48周脊柱骨密度平均升高0.01 g/cm2(P=0.0239)。
  • 髋部骨密度平均升高0.013 g/cm2(P=0.0046),T值变化分别为+0.1和+0.25。
  • 无病毒学失败,无严重或3-4级不良事件。

核心结论

  • 在病毒学抑制且骨密度低的HIV感染成人中,从替诺福韦二吡呋酯联合利托那韦增效蛋白酶抑制剂三联方案转换为拉米夫定联合利托那韦增效阿扎那韦两药方案是安全的,可提高低骨密度并降低骨转换血浆标志物和尿替诺福韦毒性标志物,观察期48周。

研究设计与样本

  • 单臂先导研究,纳入31例病毒学抑制、骨密度低、无既往耐药突变和/或对研究药物病毒学失败的患者。
  • 患者转换为利托那韦增效阿扎那韦100/300 mg联合拉米夫定300 mg每日一次,主要终点为48周时DXA测定的骨密度变化。

主要发现

  • 31例患者中4例(13%)为女性,中位年龄40岁,7例(22.5%)有骨质疏松。
  • 48周时脊柱和髋部骨密度平均(SD)变化分别为+0.01(0.03)g/cm2(P=0.0239)和+0.013(0.03)g/cm2(P=0.0046)。
  • 脊柱和髋部T值平均(SD)变化分别为+0.1(0.23)(P=0.0089)和+0.25(0.76)(P=0.0197)。
  • N-端肽和尿替诺福韦二吡呋酯毒性标志物显示显著改善。
  • 1例退出研究,2例失访;无病毒学失败,无严重或3-4级不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir disoproxil fumarate, particularly when given with a ritonavir-boosted PI, reduces bone mineral density (BMD) and increases bone turnover markers (BTMs). Ritonavir-boosted atazanavir plus lamivudine is a feasible simplified option. We evaluated whether switching from a triple ritonavir-boosted PI plus tenofovir disoproxil fumarate to a two-drug regimen of lamivudine plus ritonavir-boosted atazanavir would improve BMD. METHODS: Single-arm pilot study. Virologically suppressed patients on tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted PI with low BMD, without previous resistance mutations and/or virological failure to study drugs were switched to 100/300 mg of ritonavir-boosted atazanavir plus 300 mg of lamivudine once daily. The primary endpoint was BMD change by DXA at Week 48. RESULTS: There were 31 patients, 4 (13%) female, and median age was 40 years. Seven participants (22.5%) had osteoporosis. At 48 weeks, mean (SD) changes in spine and hip BMD were +0.01 (0.03) (P = 0.0239) and +0.013 (0.03) g/cm2 (P = 0.0046), respectively. Mean (SD) T-score changes were +0.1 (0.23) (P = 0.0089) and +0.25 (0.76) (P = 0.0197), respectively. N-telopeptide and urine tenofovir disoproxil fumarate toxicity markers showed significant improvements. One participant withdrew from the study and two were lost to follow-up. There were no virological failures, or serious or grade 3-4 adverse events. CONCLUSIONS: Switching from a tenofovir disoproxil fumarate plus ritonavir-boosted PI triple therapy to a lamivudine plus ritonavir-boosted atazanavir two-drug regimen in virologically suppressed HIV-infected adults with low BMD was safe, increased low BMD and reduced plasma markers of bone turnover and urine markers of tenofovir disoproxil fumarate toxicity over 48 weeks.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Blanco JL, Rojas J, de Lazzari E, et al. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study. J Antimicrob Chemother. 2022. PMID: 35512339. doi:10.1093/jac/dkac137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。